| 2022 | 2021 (1 May to 31 December) | |||
|---|---|---|---|---|
| In € | Amounts allocated | Amounts paid | Amounts allocated | Amounts paid |
| Fixed remuneration | 2,000,000 | 2,000,000 | 1,333,333(3) | 1,333,333(3) |
| Annual variable remuneration | 2,260,000(1) | 1,552,667(2) | 1,552,667(2) | 0 |
| Exceptional remuneration | - | - | - | - |
| Remuneration for term of office as Director | - | - | - | - |
| Benefits in kind | - | - | - | - |
| TOTAL | 4,260,000 | 3,552,667 | 2,886,000 | 1,333,333 |
(1) The variable remuneration due for year N is paid in N+1. The variable remuneration for 2022 will be paid subject to the approval of Resolution 9 by the Annual General Meeting on 21 April 2023.
(2) Variable remuneration for 2021 was paid in 2022 on a pro rata basis as the appointment of Mr Hieronimus to the position of Chief Executive Officer took effect on1 May 2021. For information, the amount on an annual basis is €2,329,000.
(3) Fixed remuneration was paid in 2021 on a pro rata basis, with the appointment of Mr Hieronimus to the position of Chief Executive Officer taking effect on 1 May 2021. For the record, the amount is €2,000,000 on an annual basis.
| In € | 2022 | 2021 (1 May to 31 December) |
|---|---|---|
| Remuneration due in respect of the financial year(1) |
Remuneration due in respect of the financial year (1)20224,260,000 |
Remuneration due in respect of the financial year (1)2021 (1 May to 31 December)2,886,000 |
| Value of performance shares granted during the financial year |
Value of performance shares granted during the financial year 20226,066,600 |
Value of performance shares granted during the financial year 2021 (1 May to 31 December)5,768,780 |
| TOTAL |
TOTAL 202210,326,600 |
TOTAL 2021 (1 May to 31 December)8,654,780 |
(1) Annual fixed and variable remuneration was paid on a pro rata basis in 2021, starting from the appointment of Mr Hieronimus on 1 May 2021. The amounts indicated for2021 cover eight months.
N/A.
N/A.
| Grant date | Number of ACAs granted | Performance conditions | Grant value(IFRS fair value) | Date of final vesting of all or part of the ACAs | Number of finally vested shares | First possible date of sale of a portion of these(2) |
|---|---|---|---|---|---|---|
| 07 October 2021 |
07 October 2021Number of ACAs granted 17,000 |
07 October 2021Performance conditions Yes |
07 October 2021Grant value(IFRS fair value) 5,768,780 |
07 October 2021Date of final vesting of all or part of the ACAs08 October 2025 |
07 October 2021Number of finally vested shares N/A |
07 October 2021First possible date of sale of a portion of these(2) 08 October 2025 |
| 13 October 2022 |
13 October 2022 Number of ACAs granted20,000 |
13 October 2022 Performance conditionsYes |
13 October 2022 Grant value(IFRS fair value)6,066,600 |
13 October 2022 Date of final vesting of all or part of the ACAs14 October 2026 |
13 October 2022 Number of finally vested sharesN/A |
13 October 2022 First possible date of sale of a portion of these(2)14 October 2026 |
(1) See the performance conditions described in chapter 5 of this document.
(2) Mr Nicolas Hieronimus, as corporate officer, shall retain 50% of the fully vested shares in registered form until the end of his term of corporate office. Mr Nicolas Hieronimushas undertaken not to enter into any risk hedging transactions.
N/A.
